Literature DB >> 9637523

Characterization of the peptide binding motif of a rhesus MHC class I molecule (Mamu-A*01) that binds an immunodominant CTL epitope from simian immunodeficiency virus.

T M Allen1, J Sidney, M F del Guercio, R L Glickman, G L Lensmeyer, D A Wiebe, R DeMars, C D Pauza, R P Johnson, A Sette, D I Watkins.   

Abstract

The majority of immunogenic CTL epitopes bind to MHC class I molecules with high affinity. However, peptides longer or shorter than the optimal epitope rarely bind with high affinity. Therefore, identification of optimal CTL epitopes from pathogens may ultimately be critical for inducing strong CTL responses and developing epitope-based vaccines. The SIV-infected rhesus macaque is an excellent animal model for HIV infection of humans. Although a number of CTL epitopes have been mapped in SIV-infected rhesus macaques, the optimal epitopes have not been well defined, and their anchor residues are unknown. We have now defined the optimal SIV gag CTL epitope restricted by the rhesus MHC class I molecule Mamu-A*01 and defined a general peptide binding motif for this molecule that is characterized by a dominant position 3 anchor (proline). We used peptide elution and sequencing, peptide binding assays, and bulk and clonal CTL assays to demonstrate that the optimal Mamu-A*01-restricted SIV gag CTL epitope was CTPYDINQM(181-189). Mamu-A*01 is unique in that it is found at a high frequency in rhesus macaques, and all SIV-infected Mamu-A*01-positive rhesus macaques studied to date develop an immunodominant gag-specific CTL response restricted by this molecule. Identification of the optimal SIV gag CTL epitope will be critical for a variety of studies designed to induce CD8+ CTL responses specific for SIV in the rhesus macaque.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9637523

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  120 in total

1.  The simian immunodeficiency virus envelope glycoprotein contains two epitopes presented by the Mamu-A*01 class I molecule.

Authors:  M Furchner; A L Erickson; T Allen; D I Watkins; A Sette; P R Johnson; C M Walker
Journal:  J Virol       Date:  1999-10       Impact factor: 5.103

2.  Inhibition of antigen presentation by the glycine/alanine repeat domain is not conserved in simian homologues of Epstein-Barr virus nuclear antigen 1.

Authors:  N W Blake; A Moghaddam; P Rao; A Kaur; R Glickman; Y G Cho; A Marchini; T Haigh; R P Johnson; A B Rickinson; F Wang
Journal:  J Virol       Date:  1999-09       Impact factor: 5.103

3.  HLA-B57-restricted cytotoxic T-lymphocyte activity in a single infected subject toward two optimal epitopes, one of which is entirely contained within the other.

Authors:  P J Goulder; Y Tang; S I Pelton; B D Walker
Journal:  J Virol       Date:  2000-06       Impact factor: 5.103

4.  Differential narrow focusing of immunodominant human immunodeficiency virus gag-specific cytotoxic T-lymphocyte responses in infected African and caucasoid adults and children.

Authors:  P J Goulder; C Brander; K Annamalai; N Mngqundaniso; U Govender; Y Tang; S He; K E Hartman; C A O'Callaghan; G S Ogg; M A Altfeld; E S Rosenberg; H Cao; S A Kalams; M Hammond; M Bunce; S I Pelton; S A Burchett; K McIntosh; H M Coovadia; B D Walker
Journal:  J Virol       Date:  2000-06       Impact factor: 5.103

5.  Prior vaccination increases the epitopic breadth of the cytotoxic T-lymphocyte response that evolves in rhesus monkeys following a simian-human immunodeficiency virus infection.

Authors:  Sampa Santra; Dan H Barouch; Marcelo J Kuroda; Jörn E Schmitz; Georgia R Krivulka; Kristin Beaudry; Carol I Lord; Michelle A Lifton; Linda S Wyatt; Bernard Moss; Vanessa M Hirsch; Norman L Letvin
Journal:  J Virol       Date:  2002-06       Impact factor: 5.103

6.  Escape in one of two cytotoxic T-lymphocyte epitopes bound by a high-frequency major histocompatibility complex class I molecule, Mamu-A*02: a paradigm for virus evolution and persistence?

Authors:  Thorsten U Vogel; Thomas C Friedrich; David H O'Connor; William Rehrauer; Elizabeth J Dodds; Heather Hickman; William Hildebrand; John Sidney; Alessandro Sette; Austin Hughes; Helen Horton; Kathy Vielhuber; Richard Rudersdorf; Ivna P De Souza; Matthew R Reynolds; Todd M Allen; Nancy Wilson; David I Watkins
Journal:  J Virol       Date:  2002-11       Impact factor: 5.103

7.  Functional analysis of frequently expressed Chinese rhesus macaque MHC class I molecules Mamu-A1*02601 and Mamu-B*08301 reveals HLA-A2 and HLA-A3 supertypic specificities.

Authors:  Scott Southwood; Christopher Solomon; Ilka Hoof; Richard Rudersdorf; John Sidney; Bjoern Peters; Angela Wahl; Oriana Hawkins; William Hildebrand; Bianca R Mothé; Alessandro Sette
Journal:  Immunogenetics       Date:  2011-01-28       Impact factor: 2.846

8.  Effects of cytotoxic T lymphocytes (CTL) directed against a single simian immunodeficiency virus (SIV) Gag CTL epitope on the course of SIVmac239 infection.

Authors:  Todd M Allen; Peicheng Jing; Briana Calore; Helen Horton; David H O'Connor; Tomas Hanke; Marian Piekarczyk; Richard Ruddersdorf; Bianca R Mothé; Carol Emerson; Nancy Wilson; Jeffrey D Lifson; Igor M Belyakov; Jay A Berzofsky; Chenxi Wang; David B Allison; David C Montefiori; Ronald C Desrosiers; Steven Wolinsky; Kevin J Kunstman; John D Altman; Alessandro Sette; Andrew J McMichael; David I Watkins
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

9.  Characterization of the peptide-binding specificity of Mamu-A*11 results in the identification of SIV-derived epitopes and interspecies cross-reactivity.

Authors:  Alessandro Sette; John Sidney; Huynh-Hoa Bui; Marie-France del Guercio; Jeff Alexander; John Loffredo; David I Watkins; Bianca R Mothé
Journal:  Immunogenetics       Date:  2005-03-04       Impact factor: 2.846

10.  High-Throughput Identification of MHC Class I Binding Peptides Using an Ultradense Peptide Array.

Authors:  Amelia K Haj; Meghan E Breitbach; David A Baker; Mariel S Mohns; Gage K Moreno; Nancy A Wilson; Victor Lyamichev; Jigar Patel; Kim L Weisgrau; Dawn M Dudley; David H O'Connor
Journal:  J Immunol       Date:  2020-02-14       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.